Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress

/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were...

Related Keywords

Germany ,Puerto Rico ,Japan ,Tokyo ,United States ,Canada ,America ,Michael Strapazon ,Trish Rowland ,Stacey Minton ,Emma Guttman Yassky ,Asia Pacific ,Davidm Reese ,Amgen ,Drug Administration ,Beigene Ltd ,Kyowa Kirin Us Research ,Exchange Commission ,A Global Specialty Pharmaceutical Company ,Therapeutics Inc ,Icahn School Of Medicine At Mount Sinai ,Jolla Institute For Immunology ,Kyowa Kirin Co Ltd ,Rd Division Of Kyowa Kirin ,Department Of Dermatology ,Investigator Global Assessment ,Numerical Rating Scale ,Waldman Professor ,Icahn School ,Mount Sinai ,Inflammatory Skin Diseases ,Yoshifumi Torii ,Kyowa Kirin ,North America ,Five Prime Therapeutics ,Thousand Oaks ,